Roctavian access for UAE patients: the EDE named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team. This page describes the named-patient and personal-importation pathways for adult UAE residents with severe hemophilia A who meet the strict eligibility profile for Roctavian. Reserve Meds frames durability honestly: meaningful but not permanent benefit for most patients, with a real possibility of returning to factor replacement therapy within a decade.

Section 1. Quick orientation

Roctavian is the brand name for valoctocogene roxaparvovec-rvox, a one-time intravenous adeno-associated virus serotype 5 (AAV5) gene therapy for adults with severe hemophilia A (congenital factor VIII deficiency with FVIII activity less than 1 IU/dL). The FDA approved Roctavian on 29 June 2023 as the first and only gene therapy for severe hemophilia A in the United States. The European Commission granted conditional marketing authorisation on 24 August 2022 on advice from the EMA. Roctavian is not registered with the Emirates Drug Establishment, and UAE capability for AAV gene therapy administration is developing rather than established. The realistic access route for a UAE patient is travel to a BioMarin-qualified Hemophilia Treatment Center in the United States or to a certified European centre for infusion, with Reserve Meds coordinating the AAV5 antibody pre-test, eligibility verification, certified-center booking, frozen logistics where applicable, and post-infusion monitoring liaison. Where Saudi Arabia's King Faisal Specialist Hospital and Research Centre or a comparable regional centre has built or is building capability, that route may also become a referral option over time; today the standard route is US or EU. Reserve Meds is the coordinator, not the prescriber. Reserved for you.

Section 2. Why UAE patients need Roctavian through a named-patient and travel pathway

The UAE operates one of the most developed pharmaceutical regulatory environments in the Gulf Cooperation Council. The Emirates Drug Establishment, which assumed 44 core regulatory services from MOHAP on 29 December 2025 under Federal Decree-Law No. 38 of 2024, maintains the national drug register and the unregistered-medicine personal-use import permit pathway. Roctavian sits in the third structural access pattern: not registered in the UAE at all. BioMarin has no local commercial agent holding national registration, and the certified-treatment-center model that gates US dispensing has no UAE-resident equivalent at the date of this page. The We the UAE 2031 healthcare strategy and the Emirati Genome Programme are accelerating local clinical capacity, but the specific operational capability for AAV5 gene-therapy administration, weekly liver-function monitoring through a corticosteroid taper, multi-year hepatic surveillance, and FVIII expression tracking, is built up over time and is not yet routinely available in-country.

For an adult UAE patient with confirmed severe hemophilia A who is AAV5-negative on the FDA-approved companion test, has no history of FVIII inhibitors, and is financially able to self-fund or has verified third-party funding, the question becomes where the infusion happens, not whether the drug is procurable. Travel to a BioMarin-qualified US Hemophilia Treatment Center is the standard route. Travel to a European certified centre under the EMA conditional authorisation is an alternative where logistics or family preference favours it. Travel to King Faisal Specialist Hospital and Research Centre in Riyadh or a comparable KSA centre may emerge as a regional option as local capability matures. The treating UAE hematologist remains the home physician and the locus of post-infusion monitoring coordination after the patient returns home.

Section 3. The EDE pathway and the cross-border travel logic for Roctavian

The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered locally is the unregistered-medicine import permit, administered through the EDE portal at ede.gov.ae from 29 December 2025. For most named-patient medicines the pathway is the obvious route: the EDE permit authorises import, the medicine ships to the UAE dispensing facility, and the treating physician administers in-country. Roctavian is different. The infusion happens at a BioMarin-qualified certified treatment center, with that center managing the day-of-infusion thawing under controlled conditions, the immediate post-infusion observation, and the weeks-to-months corticosteroid taper that follows. Infusion outside a BioMarin-qualified HTC is not supported by the manufacturer and is not the model. The practical access framework for a UAE patient therefore combines the EDE pathway (for any onward UAE-side documentation and for the home-side follow-up arrangements) with a travel and cross-border treatment plan that puts the patient at a certified centre for the infusion itself.

Reserve Meds' coordination for a Roctavian case begins with the AAV5 neutralizing antibody titer test, which is a hard pre-gate. The result must be in hand and negative on the FDA-approved companion test before any certified-center booking is initiated. Factor VIII inhibitor history must be confirmed negative through prior medical records, not patient recall alone. Baseline liver function tests (ALT, AST, alkaline phosphatase, total bilirubin) must be within an acceptable range, and contraindicating hepatic disease, significant fibrosis, active hepatitis B or C, or HIV with uncontrolled viral load, must be excluded at the treating-center level. Only when those pre-gates are confirmed does the case move forward to certified-center booking, travel arrangement, and BioMarin's dose release. The treating UAE hematologist's letter documents the diagnosis, FVIII activity less than 1 IU/dL, inhibitor history, the AAV5 result, baseline hepatic profile, and the post-infusion monitoring plan that the home centre will execute after the patient returns. Approval timelines depend more on the eligibility pipeline than on the EDE itself; companion testing, payer or self-pay funding verification, certified-center scheduling, and travel arrangements typically push the end-to-end pre-infusion window to 8 to 16 weeks for a first-time case.

Section 4. Where Roctavian gets administered, and the UAE home-side role

Roctavian is administered at BioMarin-qualified Hemophilia Treatment Centers that have completed product-specific training, vector handling certification, and infusion readiness sign-off. In the United States, that is a limited network. In Europe, BioMarin and certified centres in selected EU countries (including Germany, where a publicly disclosed pricing and reimbursement agreement with the statutory health insurance system is in place) handle EMA-authorised infusions. As of this page's review date, no UAE institution holds BioMarin certification for Roctavian administration. The dominant cross-border route is therefore travel to a certified centre, supported by the patient's UAE hematology team for pre-infusion workup and post-infusion follow-up.

The UAE home-side role is substantial. Cleveland Clinic Abu Dhabi (M42 group, Al Maryah Island), Sheikh Khalifa Medical City (SEHA network, Abu Dhabi), Tawam Hospital (Al Ain, SEHA network), American Hospital Dubai (Mayo Clinic Care Network member), King's College Hospital London Dubai, and Mediclinic City Hospital in Dubai Healthcare City carry adult hematology service lines that can manage pre-infusion eligibility workup and post-infusion liver function monitoring, FVIII activity tracking, and hepatic surveillance per HTC protocol. The home hematologist coordinates with the certified centre on the corticosteroid taper schedule (typically oral prednisone or equivalent, initiated based on ALT trends and tapered over weeks to months), the FVIII monitoring cadence, and the hepatocellular carcinoma surveillance protocol. Reserve Meds positions itself as the introducer and the documentation orchestrator between the home team and the certified centre; the clinical care itself is shared between those two clinical teams. King Faisal Specialist Hospital and Research Centre in Riyadh has been working toward AAV gene-therapy administration capability; where that develops, a KSA referral may become a regional option, with Reserve Meds adapting accordingly.

Section 5. Real cost picture for Roctavian for UAE patients

The UAE dirham is pegged to the US dollar at approximately 3.67 AED to 1 USD. Reserve Meds quotes are itemised, not bundled. The cost stack for a Roctavian case is dominated by the drug itself, with logistics and centre costs adding meaningful but secondary layers.

• Drug cost reference. US wholesale acquisition cost for Roctavian is approximately USD 2.9 million per patient for the single one-time dose, publicly disclosed by BioMarin at the June 2023 launch. That figure is a list price and is subject to confidential payer-specific net pricing and the outcomes-based warranty rebate structure in the US market. EU country-specific net pricing is confidential; the publicly reported German list reference and negotiated reimbursement amounts indicate an order-of-magnitude similar to the US WAC with country-by-country variation. International self-pay patients are quoted against the US WAC plus the full coordination, travel, infusion-center, and post-infusion monitoring cost stack, not against a discounted figure. Approximate AED reference: 2.9 million USD is roughly AED 10.6 million at the pegged rate.
• Certified-center and infusion costs. The infusion itself, the day-of preparation including thawing, the post-infusion observation window, and the structured outpatient follow-up over the first weeks all run through the certified centre and are billed separately from the drug.
• Travel, lodging, and accompaniment. A first-time Roctavian case typically requires several weeks of patient and family presence near the certified centre to clear the early ALT-elevation window and the corticosteroid taper initiation phase. Reserve Meds does not bundle travel and lodging into the medical quote; we surface the layer transparently so the family can plan.
• Post-infusion monitoring at home. The home-side UAE hematology team's monitoring services, including weekly liver function tests during the corticosteroid taper, FVIII activity monitoring at protocol-defined intervals, and ongoing hepatic surveillance, are arranged with the home institution and are billed locally.
• Regulatory and concierge. EDE permit fees, customs documentation, and Reserve Meds' concierge coordination fee are itemised separately on every firm quote.

Daman National Health Insurance (operator of the Thiqa programme for UAE nationals), GIG Gulf, Sukoon Insurance, ADNIC, and Orient Insurance each handle gene-therapy cases case by case. Coverage of a USD 2.9 million one-time therapy is exceptional and typically requires a structured pre-authorisation conversation; Thiqa, where applicable, has the broadest specialty coverage in Abu Dhabi but does not pre-commit on a case basis. We do not promise coverage. We supply the documentation that allows your insurer to assess. BioMarin's US-only outcomes-based warranty, RoctavianConnect coordination program, and US copay assistance pathway do not extend to international patients; Reserve Meds does not represent them as available outside the United States.

Section 6. Typical timeline for Roctavian in a UAE-resident case

The timeline for a Roctavian case looks different from any other drug in the Reserve Meds matrix. The single infusion is preceded by an extended eligibility pipeline that compresses or extends total time based on the speed at which the pre-gates clear. AAV5 antibody titer testing typically takes 2 to 4 weeks from sample collection to result. Factor VIII inhibitor history verification from prior medical records is documentation-bound and can move quickly with cooperative prior centres. Baseline hepatic workup is a one-week window at the home UAE hematology centre. Funding verification, self-pay or insurer assessment, is the variable that most often drives end-to-end time. Certified-center scheduling typically requires a 4 to 8 week booking horizon. Travel and lodging arrangements add a coordination layer that runs in parallel.

A reasonable end-to-end estimate from intake to infusion day is 8 to 16 weeks for a first-time UAE case, with the longer end reserved for cases where AAV5 titre is delayed, prior medical records are slow to compile, or certified-center scheduling pushes out. Post-infusion, the patient typically remains near the certified centre for several weeks to clear the early ALT-elevation window and to initiate the corticosteroid taper under the certified-center's direct supervision. After the patient returns to the UAE, weekly liver function tests during the corticosteroid taper continue under home hematology, FVIII activity monitoring at protocol-defined intervals tracks transgene expression, and hepatic surveillance continues per HTC protocol. These ranges are typical, not promises.

Section 7. What your physician needs to provide

For a Roctavian case, the documentation set is broader than a standard EDE named-patient application because the case sits at the intersection of home-country regulatory, cross-border travel, and certified-center eligibility. The treating UAE hematologist's clinical letter documents the diagnosis (congenital severe hemophilia A, FVIII activity less than 1 IU/dL), the patient's age (18 or older), the inhibitor history (negative, confirmed from prior records), the AAV5 neutralizing antibody titer result (negative on the FDA-approved companion test), the baseline hepatic profile (ALT, AST, alkaline phosphatase, total bilirubin within acceptable range), the absence of contraindicating hepatic disease (no significant fibrosis, no active hepatitis B or C, no HIV with uncontrolled viral load), prior FVIII prophylaxis and emicizumab history where applicable, and the post-infusion monitoring plan the home centre commits to executing.

Dosing per the FDA-approved label is a single intravenous infusion of 6 x 10^13 vector genomes per kilogram of body weight, prepared per patient and given once in the patient's lifetime. There is no maintenance dose and the label does not support redosing, because pre-existing AAV5 antibodies developing after the first exposure are expected to neutralize any subsequent AAV5 vector. The corticosteroid algorithm is mandatory: a prophylactic or reactive corticosteroid regimen (typically oral prednisone or equivalent) initiated based on ALT trends and tapered over weeks to months, with the taper schedule individualised by the treating HTC. Monitoring per label: weekly liver function tests during the corticosteroid taper, then tapering frequency over the first year; FVIII activity monitoring at protocol-defined intervals; hepatocellular carcinoma surveillance per HTC protocol; bleeding event tracking. The treating physician's UAE medical license number, issuing authority (MOHAP, DHA, DOH, or Sharjah Health Authority), and the supporting documentation from the certified centre complete the package on the home side.

Section 8. Common questions about Roctavian for UAE patients

Why can't Roctavian just be imported and infused in a UAE hospital? BioMarin gates Roctavian dispensing to a limited network of certified Hemophilia Treatment Centers that have completed product-specific training, vector handling certification, and infusion readiness sign-off. As of this page's review date, no UAE institution holds BioMarin certification. Infusion outside a qualified HTC is not supported by the manufacturer. The frozen biologic also requires validated dry-ice or deep-frozen shippers with continuous temperature monitoring; any excursion above the labeled storage range can disqualify the dose with no field-rework option. The model is travel to a certified centre, not home-country infusion.

Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, or Orient cover this? Each insurer assesses gene-therapy cases case by case. A USD 2.9 million one-time therapy is exceptional and typically requires a structured pre-authorisation conversation that begins months in advance. We do not promise coverage. We supply the documentation that allows your insurer to assess.

What is the durability picture? GENEr8-1 follow-up published in NEJM and subsequent journal updates show that FVIII expression declines over time in many patients. At five years, 80.8 percent of trial participants remained off regular prophylaxis, and modeled median time-to-return-to-prophylaxis ranged from 6.4 to 16.1 years. The honest framing: meaningful but not permanent benefit for most patients, with a real possibility of returning to factor replacement therapy within a decade. Roctavian is not pitched as a cure.

What is the safety profile? The most common adverse reactions in the GENEr8-1 phase 3 trial were transient ALT elevation, headache, nausea, vomiting, fatigue, abdominal pain, and infusion-related reactions. The dominant safety signal is hepatic transaminase elevation requiring corticosteroid management. There is a theoretical long-term risk of hepatocellular carcinoma related to AAV vector integration; no causal cases have been reported in the trial program, and the label requires long-term hepatic surveillance.

Why Roctavian versus Hemlibra (emicizumab)? Hemlibra is a long-running maintenance therapy dosed subcutaneously, broadly available including in jurisdictions where Roctavian is not registered, and suitable for patients with inhibitors. Roctavian offers the prospect of multi-year freedom from prophylaxis dosing for eligible patients, with the durability caveat above. Reserve Meds does not steer the choice; the treating hematologist does.

What about pediatric patients? Roctavian is FDA-approved for adults (18 and older). Pediatric coordination is not in scope at this time. No off-label use.

Section 9. Where Reserve Meds fits in Roctavian cases

Reserve Meds is a US-based concierge coordinator. We do not replace your physician, do not replace BioMarin, do not replace the certified Hemophilia Treatment Center, and do not replace your home hematology team. For Roctavian specifically, the orchestration we provide includes AAV5 neutralizing antibody titre testing coordination as the hard pre-gate, factor VIII inhibitor history verification, baseline hepatic workup documentation review, certified-center introduction and booking support, travel and lodging coordination support for the patient and accompanying family member, frozen-logistics oversight in the supply chain to the certified centre where applicable, and post-infusion monitoring liaison between the certified centre and the home UAE hematology team. We treat this drug as a frozen specialty handoff comparable to autologous cell products in choreography, even though Roctavian is allogeneic in nature. We do not coordinate infusion outside a BioMarin-qualified HTC and we do not propose home or domestic-hospital infusion in the patient's country of residence. The corticosteroid algorithm is mandatory and Reserve Meds coordinates the post-infusion monitoring window around it. Durability is framed honestly in every patient conversation. No prior Reserve Meds case experience exists for Roctavian at the date of this page. Standard NPP coordination applies, with the drug-specific operating notes above treated as binding.

Section 10. Next step

If your treating UAE hematologist has identified Roctavian as a potential next step for your severe hemophilia A and you are considering the cross-border pathway, the next step is the waitlist. We confirm preliminary eligibility within 24 to 48 hours, initiate the AAV5 antibody pre-test conversation with your hematologist, and assemble the certified-center coordination kit. Reserved for you.

---

This guide is informational, not medical or legal advice. The named-patient framework requires a licensed UAE physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.